




DRUG DISCOVERY

## **The Future of Metabolomics**

Building competitive advantage in drug discovery, clinical development and diagnostics

By Dr CL Barton

 [Table of Contents](#)

## **Dr Cheryl L Barton**

Dr C L Barton has over 10 year's practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a European Bank.

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs/technologies and isolate the key drivers within the industry sector. For more details visit [www.pharmavision.co.uk](http://www.pharmavision.co.uk)

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Future of Metabolomics

<b>Executive Summary</b>	<b>10</b>
Introduction	10
Platform technologies in metabolomics	11
Regulatory and standardization issues	12
Metabolomics in drug discovery & preclinical development	13
Metabolomics in clinical drug development	14
The role of metabolomics for marketed drugs	15
Metabolomics in diagnostics and health screening	16
Market size, alliances, acquisitions and future directions	17
<b>Chapter 1            Introduction</b>	<b>20</b>
Summary	20
What is metabolomics?	21
The metabolome	23
Metabolomics' relationship with other 'omics technologies	24
Uses of metabolomics in drug discovery and development	26
Advantages of metabolomics	27
Challenges to the field of metabolomics	28
Conclusions	29
<b>Chapter 2            Platform technologies in                           metabolomics</b>	<b>32</b>
Summary	32
Introduction	33
Technologies for metabolomics	33

Mass Spectrometry (MS)	33
Nuclear Magnetic Resonance spectroscopy (NMR)	36
MS versus NMR	37
Other spectroscopic and chromatographic techniques	39
Fourier-transform infrared spectroscopy (FTIR)	39
Electrochemical array	39
<b>Emerging technologies</b>	<b>40</b>
Technology developments	40
Metabolomics in individual cells	41
<b>Experimental design and analysis</b>	<b>41</b>
Data transformation, peak deconvolution and quantification	42
Metabolite identification	42
Data mining and analysis: Chemometrics	44
Databases for metabolic pathway analysis	48
<b>Conclusions</b>	<b>50</b>

## **Chapter 3            Regulatory and standardization issues            52**

<b>Summary</b>	<b>52</b>
<b>Introduction</b>	<b>53</b>
<b>Regulatory issues</b>	<b>53</b>
US Food and Drug Administration	53
European Medicines Agency (EMA) and the Japanese Ministry of Health and Welfare (MHLW)	54
<b>Standardization in metabolomics</b>	<b>55</b>
<b>Incentives for pharma</b>	<b>56</b>
<b>Conclusions</b>	<b>56</b>

## **Chapter 4            Metabolomics in drug discovery & preclinical development            58**

<b>Summary</b>	<b>58</b>
<b>Introduction</b>	<b>59</b>
<b>Target identification and validation</b>	<b>60</b>
<b>Lead prioritization</b>	<b>61</b>
<b>Pharmacology, efficacy and mechanism of action studies</b>	<b>63</b>
Case study: Lipomics Technologies Inc	63
Case study: SIDMAP	64
<b>Preclinical studies for non-target effects</b>	<b>65</b>



## **Chapter 7                      Metabolomics in diagnostics and health screening                      106**

<b>Summary</b>	<b>106</b>
<b>Introduction</b>	<b>107</b>
<b>Diagnostic applications of metabolomics</b>	<b>108</b>
Case study: A NMR-based diagnostic test for atherosclerosis	108
Case study: A diagnostic test for coronary heart disease	109
Case study: A metabolic signature for motor neuron disease	111
Case study: novel biomarkers for pre-eclampsia	112
Case study: the Magnetic Resonance Diagnostics Centre	113
<b>Metabolomics for population screening</b>	<b>115</b>
Case study: newborn screening by Pediatrix Screening	116
Case study: the MolPAGE Consortium	118
<b>Conclusions</b>	<b>119</b>

## **Chapter 8                      Market size, alliances, acquisitions and future directions                      122**

<b>Summary</b>	<b>122</b>
<b>Introduction</b>	<b>123</b>
<b>Saving costs in preclinical drug development</b>	<b>124</b>
<b>Saving costs in clinical studies</b>	<b>125</b>
<b>Cost effective diagnostics</b>	<b>126</b>
<b>Key metabolomics companies and academic groups</b>	<b>127</b>
<b>Patent position</b>	<b>132</b>
<b>Current use of metabolomics in the pharma industry</b>	<b>135</b>
<b>The metabolomics market</b>	<b>138</b>
<b>Conclusions</b>	<b>139</b>

## **Chapter 9                      Appendix                      142**

<b>Index</b>	<b>142</b>
<b>Bibliography</b>	<b>144</b>
<b>Endnotes</b>	<b>150</b>

# List of Figures

Figure 1.1:	Established biochemical pathways	21
Figure 1.2:	Number of publications in metabolomics, 1997-2005	22
Figure 1.3:	The human metabolome	24
Figure 1.4:	The 'omics technologies	25
Figure 1.5:	Preclinical and clinical uses of metabolomics	26
Figure 2.6:	Mass spectrometry – a summary	34
Figure 2.7:	NMR spectroscopy	36
Figure 2.8:	<sup>1</sup> H NMR spectrum of urine showing functional windows	37
Figure 2.9:	Analysis of metabolomics data	42
Figure 2.10:	Examples of PCA and PLS-DA plots for biomarker discovery	45
Figure 2.11:	Algorithms for metabolomic data analysis	46
Figure 2.12:	Metabolic pathway map: biosynthesis of isoleucine	48
Figure 3.13:	The metabolomics standardization initiative	55
Figure 4.14:	Metabolomics for target identification	60
Figure 4.15:	Metabolon case study: prioritization of lead anti-infective compounds	62
Figure 4.16:	Metabolomics for toxicity screening in preclinical drug development	65
Figure 4.17:	Principal component analysis of urine from rats treated with a vasculitis causing compound	68
Figure 4.18:	Operation of the COMET expert system for predicting main organ toxicity	70
Figure 4.19:	Organization of the Liver Toxicity Biomarker Study	75
Figure 5.20:	Drug development: cumulative cost per step including failures	79
Figure 5.21:	Uses of metabolomics in clinical drug development	80
Figure 5.22:	Pharmacogenomic approach to patient stratification in clinical trials	81
Figure 5.23:	Patient stratification: value for business and public health from the use of pharmacogenomics in Herceptin development	82
Figure 5.24:	The pharmacometabonomic hypothesis tested in rats	83
Figure 5.25:	Metabolomic biomarker discovery protocol for sorafenib	85
Figure 5.26:	Biomarker discovery at Phenomenome Discoveries Inc: Colorectal Cancer example	87
Figure 5.27:	NMR spectra of urine from asthmatic patients and healthy individuals	89
Figure 6.28:	Metabolite expression in adipocytes by five protease inhibitors	96
Figure 6.29:	Metabolic flux analysis using carbon-13 labelled glucose as a tracer	99
Figure 7.30:	Relationship between LDL particles and LDL cholesterol, HDL cholesterol and triglycerides	109
Figure 7.31:	Classification of coronary artery disease with metabolomics	110
Figure 7.32:	Metabolomic analysis of data from patients with ALS and controls	111
Figure 7.33:	Diagnosis of community acquired pneumonia using metabolomics: the MRDC project	114
Figure 7.34:	PCA and metabolite correlation maps for diagnosis of pulmonary diseases from the Magnetic Resonance Diagnostics Centre	115
Figure 8.35:	Better data improves productivity	123
Figure 8.36:	The biology-centric drug discovery process	125

# List of Tables

Table 1.1:	Advantages of metabolomics	27
Table 2.2:	Comparison of NMR vs. MS for metabolomics applications	38
Table 2.3:	Publicly available databases of metabolite spectra	43
Table 2.4:	Commercial metabolite identification software	44
Table 2.5:	Metabolomics data analysis software	47
Table 2.6:	Publicly available databases of metabolic pathways	49
Table 4.7:	Strengths and limitations of metabolomics in toxicology	72
Table 4.8:	Metabolites often detected in metabolomic studies	73
Table 6.9:	Number of metabolites up- and down-regulated by five protease inhibitors	97
Table 6.10:	A summary of statistically significant metabolomic or metabolite measurements relevant to organ transplantation or organ dysfunction	102
Table 7.11:	Metabolic disorders identified by the Pediatrix StepOne™ test	117
Table 7.12:	Partners in the MolPAGE consortium	118
Table 8.13:	Leading suppliers and service companies in metabolomics	128
Table 8.14:	Bioinformatics/Chemometrics companies interested in metabolomics	130
Table 8.15:	Key academic centers for metabolomics research	131
Table 8.16:	Number of patents issued by metabolomics-based biomarker discovery and service companies	132
Table 8.17:	Patents for metabolomic methods	133
Table 8.18:	Patents applying metabolomic technologies to drug/diagnostic development	134
Table 8.19:	Alliances between leading metabolomics companies and pharma, academia and platform developers	136
Table 8.20:	Alliances between leading metabolomics companies and pharma, academia and platform developers	137
Table 8.21:	Metabolomics market size and forecast: 2005-2012 (\$bn)	138